Skip to content

Free cash flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$816M+126%
ADMA Biologics logo
ADMA BiologicsADMA
$55.71M+329%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
-$10.25M-18.1%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-$8.61M-35.5%
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Calculated from Lifecore Biomedical, Inc.’s reported figures.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s free cash flow?
Lifecore Biomedical, Inc. (LFCR) reported free cash flow of $3.58M in Q1 2026.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.